Research programme: small molecule therapeutics: PhoreMost/Vipergen ApS
Latest Information Update: 29 Sep 2021
At a glance
- Originator Phoremost; Vipergen ApS
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 22 Sep 2021 Small molecule therapeutics are available for licensing as of 22 Sep 2021. https://www.vipergen.com/partnering/
- 20 Sep 2021 Small molecule therapeutics are available for licensing as of 20 Sep 2021. https://www.phoremost.com/
- 14 Sep 2021 PhoreMost and Vipergen ApS agree to co-develop small molecule therapeutics for Cancer